Alterations in CD46-mediated Tr1 regulatory T cells in patients with multiple sclerosis

Journal of Clinical Investigation

Volumn 116, Issue 12, 2006, Pages 3252-3257

  Astier, Anne L ^a   Meiffren, Gregory ^b   Freeman, Samuel ^a   Hafler, David A ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIBODY; GAMMA INTERFERON; GLATIRAMER; INTERLEUKIN 10; MEMBRANE COFACTOR PROTEIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD28; MONOCLONAL ANTIBODY CD46; STEROID;

ADULT; ARTICLE; AUTOIMMUNE DISEASE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ADULT; ANTIGENS, CD28; ANTIGENS, CD46; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; FLOW CYTOMETRY; HUMANS; INTERLEUKIN-10; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PROTEIN ISOFORMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; T-LYMPHOCYTES, REGULATORY;

EID: 33845302957     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI29251     Document Type: Article

References (47)

1. Hafler, D.A., et al. 2005. Multiple sclerosis. Immunol. Rev. 204:208-231.
2. Adorini, L. 2004. Immunotherapeutic approaches in multiple sclerosis. J. Neurol. Sci. 223:13-24.
3. Hohlfeld, R., and Wekerle, H. 2004. Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines. Proc. Natl. Acad. Sci. U. S. A. 101(Suppl. 2):14599-14606.
4. Hafler, D.A., and De Jager, P.L. 2005. Applying a new generation of genetic maps to understand human inflammatory disease. Nat. Rev. Immunol. 5:83-91.
5. Feldmann, M., and Steinman, L. 2005. Design of effective immunotherapy for human autoimmunity. Nature. 435:612-619.
6. Kohm, A.P., et al. 2006. Cutting edge: anti-CD25 monoclonal antibody injection results in the functional inactivation, not depletion, of CD4+CD25+ T regulatory cells. J. Immunol. 176:3301-3305.
7. Antel, J.P., Freedman, M.S., Brodovsky, S., Francis, G.S., and Duquette, P. 1989. Activated suppressor cell function in severely disabled patients with multiple sclerosis. Ann. Neurol. 25:204-207.
8. Cattaneo, R. 2004. Four viruses, two bacteria, and one receptor: membrane cofactor protein (CD46) as pathogens' magnet. J. Virol. 78:4385-4388.
9. Russell, S. 2004. CD46: a complement regulator and pathogen receptor that mediates links between innate and acquired immune function. Tissue Antigens. 64:111-118.
10. Kemper, C., Verbsky, J.W., Price, J.D., and Atkinson, J.P. 2005. T-cell stimulation and regulation: with complements from CD46. Immunol. Res. 32:31-44.
11. Astier, A., Trescol-Biemont, M.C., Azocar, O., Lamouille, B., and Rabourdin-Combe, C. 2000. Cutting edge: CD46, a new costimulatory molecule for T cells, that induces p120CBL and LAT phosphorylation. J. Immunol. 164:6091-6095.
12. Zaffran, Y., et al. 2001. CD46/CD3 costimulation induces morphological changes of human T cells and activation of Vav, Rac, and extracellular signal-regulated kinase mitogen-activated protein kinase. J. Immunol. 167:6780-6785.
13. Russell, S.M., Loveland, B.E., Johnstone, R.W., Thorley, B.R., and McKenzie, I.F. 1992. Functional characterisation of alternatively spliced CD46 cytoplasmic tails. Transplant. Proc. 24:2329-2330.
14. Marie, J.C., et al. 2002. Linking innate and acquired immunity: divergent role of CD46 cytoplasmic domains in T cell induced inflammation. Nat. Immunol. 3:659-666.
15. Kemper, C., et al. 2003. Activation of human CD4(+) cells with CD3 and CD46 induces a T-regulatory cell 1 phenotype. Nature. 421:388-392.
16. Grossman, W.J., et al. 2004. Differential expression of granzymes A and B in human cytotoxic lymphocyte subsets and T regulatory cells. Blood. 104:2840-2848.
17. Sanchez, A., Feito, M.J., and Rojo, J.M. 2004. CD46-mediated costimulation induces a Th1-biased response and enhances early TCR/CD3 signaling in human CD4+ T lymphocytes. Eur. J. Immunol. 34:2439-2448.
18. Lan, R.Y., Ansari, A.A., Lian, Z.X., and Gershwin, M.E. 2005. Regulatory T cells: development, function and role in autoimmunity. Autoimmun. Rev. 4:351-363.
19. Bach, J.F. 2001. Non-Th2 regulatory T-cell control of Th1 autoimmunity. Scand. J. Immunol. 54:21-29.
20. Faria, A.M., and Weiner, H.L. 2005. Oral tolerance. Immunol. Rev. 206:232-259.
21. Hori, S., Nomura, T., and Sakaguchi, S. 2003. Control of regulatory T cell development by the transcription factor Foxp3. Science. 299:1057-1061.
22. Baecher-Allan, C.M., and Hafler, D.A. 2005. Functional analysis of highly defined, FACS-isolated populations of human regulatory CD4+CD25+ T cells. Clin. Immunol. 117:192; discussion 193.
23. Battaglia, M., Gregori, S., Bacchetta, R., and Roncarolo, M.G. 2006. Tr1 cells: from discovery to their clinical application. Semin. Immunol. 18:120-127.
24. Groux, H., et al. 1997. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature. 389:737-742.
25. Bettelli, E., et al. 1998. IL-10 is critical in the regulation of autoimmune encephalomyelitis as demonstrated by studies of IL-10- and IL-4-deficient and transgenic mice. J. Immunol. 161:3299-3306.
26. Cua, D.J., Groux, H., Hinton, D.R., Stohlman, S.A., and Coffman, R.L. 1999. Transgenic interleukin 10 prevents induction of experimental autoimmune encephalomyelitis. J. Exp. Med. 189:1005-1010.
27. Balashov, K.E., Smith, D.R., Khoury, S.J., Hafler, D.A., and Weiner, H.L. 1997. Increased interleukin 12 production in progressive multiple sclerosis: induction by activated CD4+ T cells via CD40 ligand. Proc. Natl. Acad. Sci. U. S. A. 94:599-603.
28. Van Boxel-Dezaire, A.H., et al. 1999. Decreased interleukin-10 and increased interleukin-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis. Ann. Neurol. 45:695-703.
29. Viglietta, V., Baecher-Allan, C., Weiner, H.L., and Hafler, D.A. 2004. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J. Exp. Med. 199:971-979.
30. Haas, J., et al. 2005. Reduced suppressive effect of CD4+CD25high regulatory T cells on the T cell immune response against myelin oligodendrocyte glycoprotein in patients with multiple sclerosis. Eur. J. Immunol. 35:3343-3352.
31. Huan, J., et al. 2005. Decreased FOXP3 levels in multiple sclerosis patients. J. Neurosci. Res. 81:45-52.
32. Christen, U., and von Herrath, M.G. 2004. Initiation of autoimmunity. Curr. Opin. Immunol. 16:759-767.
33. Bluestone, J.A., and Tang, Q. 2005. How do CD4+CD25+ regulatory T cells control autoimmunity? Curr. Opin. Immunol. 17:638-642.
34. Brod, S.A., Nelson, L.D., Khan, M., and Wolinsky, J.S. 1997. IFN-beta 1b treatment of relapsing multiple sclerosis has no effect on CD3-induced inflammatory or counterregulatory anti-inflammatory cytokine secretion ex vivo after nine months. Int. J. Neurosci. 90:135-144.
35. Kozovska, M.E., et al. 1999. Interferon beta induces T-helper 2 immune deviation in MS. Neurology. 53:1692-1697.
36. Johnstone, R.W., Russell, S.M., Loveland, B.E., and McKenzie, I.F. 1993. Polymorphic expression of CD46 protein isoforms due to tissue-specific RNA splicing. Mol. Immunol. 30:1231-1241.
37. Vandenbark, A.A. 2005. TCR peptide vaccination in multiple sclerosis: boosting a deficient natural regulatory network that may involve TCR-specific CD4+CD25+ Treg cells. Curr. Drug Targets Inflamm. Allergy. 4:217-229.
38. Correale, J., et al. 1995. Patterns of cytokine secretion by autoreactive proteolipid protein-specific T cell clones during the course of multiple sclerosis. J. Immunol. 154:2959-2968.
39. Clerici, M., et al. 2001. Single-cell analysis of cytokine production shows different immune profiles in multiple sclerosis patients with active or quiescent disease. J. Neuroimmunol. 121:88-101.
40. Ozenci, V., et al. 1999. Multiple sclerosis: levels of interleukin-10-secreting blood mononuclear cells are low in untreated patients but augmented during interferon-beta-1b treatment. Scand. J. Immunol. 49:554-561.
41. Wong, T.C., Yant, S., Harder, B.J., Korte-Sarfaty, J., and Hirano, A. 1997. The cytoplasmic domains of complement regulatory protein CD46 interact with multiple kinases in macrophages. J. Leukoc. Biol. 62:892-900.
42. Ludford-Menting, M.J., et al. 2002. A functional interaction between CD46 and DLG4: a role for DLG4 in epithelial polarization. J. Biol. Chem. 277:4477-4484.
43. Hirano, A., Yang, Z., Katayama, Y., Korte-Sarfaty, J., and Wong, T.C. 1999. Human CD46 enhances nitric oxide production in mouse macrophages in response to measles virus infection in the presence of gamma interferon: dependence on the CD46 cytoplasmic domains. J. Virol. 73:4776-4785.
44. Lee, S.W., et al. 2002. CD46 is phosphorylated at tyrosine 354 upon infection of epithelial cells by Neisseria gonorrhoeae. J. Cell Biol. 156:951-957.
45. Wang, G., Liszewski, M., Chan, A., and Atkinson, J. 2000. Membrane cofactor protein (MCP; CD46): isoform-specific tyrosine phosphorylation. J. Immunol. 164:1839-1846.
46. Brinkkoetter, P.T., et al. 2005. Altered CD46-mediated T cell co-stimulation in haemodialysis patients. Clin. Exp. Immunol. 139:534-541.
47. Bacchetta, R., Gregori, S., and Roncarolo, M.G. 2005. CD4+ regulatory T cells: mechanisms of induction and effector function. Autoimmun. Rev. 4:491-496.